Core Insights - Boji Pharmaceutical's stock closed at 9.15 yuan, up 2.58%, with a rolling PE ratio of 78.60 times and a total market capitalization of 3.505 billion yuan [1] - The average PE ratio for the medical services industry is 46.70 times, with a median of 48.76 times, placing Boji Pharmaceutical at the 34th position in the industry ranking [1] - As of September 30, 2024, the number of shareholders for Boji Pharmaceutical is 22,995, a decrease of 4,424 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Company Overview - Boji Pharmaceutical Co., Ltd. primarily provides comprehensive "one-stop" CRO services for domestic and international pharmaceutical companies and research institutions, including clinical research services, preclinical research services, CDMO services, consulting services, independent preclinical R&D, and technology transfer services [1] - The company has received several accolades, including being ranked 8th in the "Top 20 Chinese Pharmaceutical CRO Companies 2024," recognized in the "Top 50 Chinese Pharmaceutical R&D Companies 2023," and awarded the "Excellence Achievement Award" for being a high-tech enterprise for 15 consecutive years [1] Financial Performance - In the latest quarterly report for 2024, Boji Pharmaceutical achieved a revenue of 555.6 million yuan, representing a year-on-year increase of 55.01%, and a net profit of 43.2778 million yuan, reflecting a year-on-year growth of 87.98%, with a gross profit margin of 32.19% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Boji Pharmaceutical, which has a current stock price of 9.1 yuan and a rolling PE ratio of 78.17 times, significantly higher than the industry average of 46.29 times [1][2] - Boji Pharmaceutical's total market capitalization is 3.486 billion yuan, ranking 35th in the medical services industry based on PE ratio [1][2] - As of the third quarter of 2024, 51 institutions hold shares in Boji Pharmaceutical, with a total of 2.6617 million shares valued at 0.023 billion yuan [1] Group 2 - The company specializes in providing comprehensive CRO services for pharmaceutical companies and research institutions, including clinical research, preclinical research, CDMO services, and technology transfer [1] - Boji Pharmaceutical has received several accolades, including being ranked 8th among the top 20 CRO companies in China for 2024 and recognized as one of the top 50 pharmaceutical R&D companies in 2023 [1] - The latest financial results for the third quarter of 2024 show that the company achieved a revenue of 0.556 billion yuan, representing a year-on-year increase of 55.01%, and a net profit of 43.2778 million yuan, up 87.98% year-on-year, with a gross profit margin of 32.19% [1]